In silico Drug Design of Natural Apolipoprotein E4 Inhibitors for Alzheimer's Disease Management

Fawzia A Alshubaily, Hayat M. AlBishi, Sumaih M. Alnowihi

Abstract


Background: Alzheimer's disease (AD) is the most common form of dementia among the elderly and one of the most difficult public health issues. The APoE4 allele is the main risk factor for late-onset sporadic AD.

Methods: This study chose phytochemicals from Ginkgo biloba because of their well-documented neuroprotective properties. A total of 258 G. biloba compounds were obtained from the LOTUS database and screened against the Apolipoprotein E4 (ApoE4) protein using the in silico method. Physicochemical and ADMET properties prediction assessment was conducted using the ADMETLab 3.0 web tool. 

Result: The hit compounds quercetin, saccharic acid, acacetin, and L-tyrosine were discovered to strongly bind to ApoE4 protein and interact with key ApoE4 protein residues. In addition, these compounds had several amino acid interactions in common with the control compounds. Furthermore, these four compounds have distinct ADMET profiles, and the expected properties, such as solubility, permeability, and toxicity, fall within acceptable limits, making them potential drug candidates.

Conclusion: The compounds (quercetin, saccharic acid, acacetin, and L-tyrosine) can be used as ApoE4 inhibitors to manage AD.

Keywords: Alzheimer's disease; dementia; apolipoprotein E4; Ginkgo biloba; drug-likeness 


Full Text:

PDF

References


Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimer's & Dementia, (2012); 8(2): 131-168.

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, (2002); 297(5580): 353-356.

Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet, (2006); 368(9533): 387-403.

Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, (2007); 316(5825): 750-754.

Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Molecular Neurodegeneration, (2011); 6(1): 27.

Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset alzheimer's disease revisited. Alzheimer's & Dementia, (2016); 12(6): 733-748.

McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, (2021); 16(1): 49.

Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, (2019); 15(9): 501-518.

Tamimi NA, Ellis P. Drug development: from concept to marketing! Nephron Clinical Practice, (2009); 113(3): 125-131.

Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. British Journal of Pharmacology, (2011); 162(6): 1239-1249.

Talevi A. Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects. Methods in Molecular Biology, (2024); 27141-20.

Ashraf SA, Elkhalifa AEO, Mehmood K, Adnan M, Khan MA, et al. Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of okra-derived ligand abscisic acid targeting signaling proteins involved in the development of diabetes. Molecules, (2021); 26(19): 5957.

Rutz A, Sorokina M, Galgonek J, Mietchen D, Willighagen E, et al. The LOTUS initiative for open knowledge management in natural products research. Elife, (2022); 11: e70780.

Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, et al. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arteriosclerosis, Thrombosis, and Vascular Biology, (2014); 34(10): 2246-2253.

Tsilimigras DI, Thanopoulou K, Salagianni M, Siasos G, Oikonomou E, et al. Rosuvastatin attenuates progression of atherosclerosis and reduces serum IL6 and CCL2 levels in apolipoprotein-e-deficient mice. In Vivo, (2023); 37(3): 994-1002.

Kocis P, Tolar M, Yu J, Sinko W, Ray S, et al. Elucidating the Aβ42 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs, (2017); 31(6): 495-509.

Elkhalifa AEO, Al-Shammari E, Kuddus M, Adnan M, Sachidanandan M, et al. Structure-based multi-targeted molecular docking and dynamic simulation of soybean-derived isoflavone genistin as a potential breast cancer signaling proteins inhibitor. Life, (2023); 13(8): 1739.

Fu L, Shi S, Yi J, Wang N, He Y, et al. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Research, (2024); 52(W1): 422-431.

Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet, (2011); 377(9770): 1019-1031.

Ferreira D, Perestelo-Perez L, Westman E, Wahlund LO, Sarria A, Serrano-Aguilar P. Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Frontiers in Aging Neuroscience, (2014); 6: 47.

Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurology, (2021); 20(1): 68-80.

Sait KHW, Alam Q, Anfinan N, Al-Ghamdi O, Malik A, et al. Structure-based virtual screening and molecular docking for the identification of potential novel EGFRkinase inhibitors against ovarian cancer. Bioinformation, (2019); 15(4): 287-294.

Nazam N, Lone MI, Hamid A, Qadah T, Banjar A, et al. Dimethoate induces dna damage and mitochondrial dysfunction triggering apoptosis in rat bone-marrow and peripheral blood cells. Toxics, (2020); 8(4): 80.

Sait KHW, Mashraqi M, Khogeer AA, Alzahrani O, Anfinan NM, et al. Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents. Bioinformation, (2020); 16(11): 882-887.

Alqahtani LS, Alkathiri AS, Alzahrani A, Alghamdi RM, Alamri WA, et al. Structure-Based Virtual Screening of Antiviral Compounds Targeting the Norovirus RdRp Protein. Advancements in Life Sciences, (2024); 11(2): 488-492.

Panda SS, Jhanji N. Natural Products as Potential Anti-Alzheimer Agents. Current Medicinal Chemistry, (2020); 27(35): 5887-5917.

Mohd Sairazi NS, Sirajudeen KNS. Natural Products and Their Bioactive Compounds: Neuroprotective Potentials against Neurodegenerative Diseases. Evidence-Based Complementary and Alternative Medicine, (2020); 2020: 6565396.

Hori T, Ridge RW, Tulecke W, Del Tredici P, Trémouillaux-Guiller J, Tobe H. Ginkgo biloba a global treasure: from biology to medicine. Springer Science & Business Media, (2012).

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurology, (2012); 11(10): 851-859.

Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Archives of neurology, (1998); 55(11): 1409-1415.

Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry, (1996); 29(2): 47-56.

Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA, (1997); 278(16): 1327-1332.

Napryeyenko O, Borzenko I, Group G-NS. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung, (2007); 57(1): 4-11.

Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging & Mental Health, (2009); 13(2): 183-190.




DOI: http://dx.doi.org/10.62940/als.v12i4.3735

Refbacks

  • There are currently no refbacks.